EGFR and lung carcinoma: Additionally, we suggest that additional pre-clinical studies be initiated to evaluate the efficacy of dacomitinib as a possible therapeutic for EGFR-mutant lung cancer patients harboring ECD mutations, which are routinely observed as lung cancer somatic mutations (Fig. 7f,g).